https://cgas-signal.com/index.....php/image-resolution
Experimental design 238 BRCA1 VUS - comprising most BRCA1 VUS known within the Netherlands and Belgium - had been tested with their capacity to complement Brca1 deficient mouse ES cells in HRR, making use of cisplatin and olaparib sensitivity assays and a DR-GFP HRR assay. Assays were validated making use of 25 known benign and 25 known pathogenic BRCA1 variations. For assessment of pathogenicity by a multifactorial chance analysis method, we obtained clinical and genetic information for functionally
Like
Comment
Share
